Literature DB >> 2877115

Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function.

F Güttler, H Lou.   

Abstract

Thirty years ago it was observed that the synthesis of serotonin, dopamine and norepinephrine was impaired in untreated phenylketonuria (PKU) as judged either by a decreased concentration in the blood or decreased excretion in the urine of these neurotransmitters, or of their metabolites, 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA). Fifteen years later, when early treatment of PKU with a phenylalanine restricted diet was routinely introduced, an inverse relationship was found between phenylalanine levels and the urinary excretion of dopamine and serotonin. An inverse relationship between blood phenylalanine levels and cerebrospinal fluid (CSF) concentrations of HVA and 5-HIAA has repeatedly been reported during the past 10 years. Recently, the effect of the discontinuation of diet in PKU on the synthesis of dopamine, norepinephrine and serotonin has been examined, and the possible relationship between low levels of these neurotransmitters and impaired performance on neuropsychological tests has been evaluated. In some PKU patients the performance on neuropsychological tests of higher integrative function is impaired after discontinuation of diet, especially when blood phenylalanine values exceed 1200 mumol/L, and the patients often complain of lack of concentration and emotional instability. When these patients return to a 'relaxed' phenylalanine restricted, tyrosine enriched diet, the impaired neuropsychological and behavioural functions appear to be reversible. One mechanism may involve an impaired synthesis of dopamine and serotonin, as the improvement is accompanied by an increase in dopamine and serotonin excretion and a significant increase in CSF concentrations of HVA and 5-HIAA.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877115     DOI: 10.1007/bf01799701

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

1.  Decreased 5-hydroxytryptophan decarboxylase activity in phenylketonuria.

Authors:  C M PARE; M SANDLER; R S STACEY
Journal:  Lancet       Date:  1958-11-22       Impact factor: 79.321

2.  The concentration of adrenaline in human plasma and its relation to mental activity.

Authors:  H WEIL-MALHERBE
Journal:  J Ment Sci       Date:  1955-10

3.  Tryptophan hydroxylation in mammalian systems.

Authors:  W Lovenberg; E Jequier; A Sjoerdsma
Journal:  Adv Pharmacol       Date:  1968

Review 4.  Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome.

Authors:  S E Waisbren; R R Schnell; H L Levy
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

5.  Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia.

Authors:  I J Butler; M E O'Flynn; W E Seifert; R R Howell
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

6.  Serotonin and dopamine synthesis in phenylketonuria.

Authors:  H C Curtius; A Niederwieser; M Viscontini; W Leimbacher; H Wegmann; B Blehova; F Rey; J Schaub; H Schmidt
Journal:  Adv Exp Med Biol       Date:  1981       Impact factor: 2.622

7.  Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine.

Authors:  H K Berry; M K Bofinger; M M Hunt; P J Phillips; M B Guilfoile
Journal:  Pediatr Res       Date:  1982-09       Impact factor: 3.756

8.  Early-treated phenylketonuria: neuropsychologic consequences.

Authors:  R L Brunner; M K Jordan; H K Berry
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

9.  The use of deuterated phenylalanine for the elucidation of the phenylalanine-tyrosine metabolism.

Authors:  H C Curtius; J A Völlmin; K Baerlocher
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

10.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more
  30 in total

1.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

2.  Iatrogenic skin lesions in phenylketonuric children due to a low tyrosine intake.

Authors:  B François; M Diels; M de la Brassinne
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

3.  Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 mice.

Authors:  Tanja Scherer; Gabriella Allegri; Christineh N Sarkissian; Ming Ying; Hiu Man Grisch-Chan; Anahita Rassi; Shelley R Winn; Cary O Harding; Aurora Martinez; Beat Thöny
Journal:  J Inherit Metab Dis       Date:  2018-03-08       Impact factor: 4.982

4.  Prolactin, a marker for cerebral dopamine deficiency in patients suffering from phenylketonuria (PKU)?

Authors:  J Denecke; W Schlegel; G H Koch; R Feldmann; E Harms; J Weglage
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

5.  Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Authors:  Huiling Peng; Dawn Peck; Desirée A White; Shawn E Christ
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

6.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

Review 7.  Large neutral amino acids in the treatment of PKU: from theory to practice.

Authors:  Francjan J van Spronsen; Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2010-10-26       Impact factor: 4.982

Review 8.  A prefrontal dysfunction model of early-treated phenylketonuria.

Authors:  M C Welsh
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Phenylketonuria: treatment in adolescence and adult life.

Authors:  D P Brenton; A C Tarn; J C Cabrera-Abreu; M Lilburn
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Interpretation of plasma amino acids in the follow-up of patients: the impact of compartmentation.

Authors:  Claude Bachmann
Journal:  J Inherit Metab Dis       Date:  2008-01-31       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.